Loading patent…
AssigneeSchering Corporation
InventorsEdward Paul Bowman, Daniel J. Cua, Robert A. Kastelein, Kathy Lynn Miller, Melanie A. Kleinschek, Kristian S. Bak-Jensen, Katia Boniface, Brent S. McKenzie, Rene de Waal Malefyt
Estimating the term…
Methods and compositions are provided for the treatment of immune disorders, such as autoimmune diseases, or cancers, involving combination therapy with agents that inhibit the development or maintenance of Th17 cells. Treatment regimens are provided in which an antagonist of a pro-inflammatory cytokine is administered for a time sufficient to alleviate signs and symptoms of an acute phase flare-up of the autoimmune disease, or cancer, and treatment with an antagonist of IL-23 is continued for a longer time to prevent recurrence of the acute event. Antagonists of PGE2 and CD161 are also disclosed for use in treatment of autoimmune, inflammatory and proliferative disorders.
A method of treating a subject having cancer or exhibiting a flare up of an autoimmune disease, comprising:
(canceled)
(canceled)
7-9. (canceled)
11-14. (canceled)
(canceled)
A pharmaceutical composition comprising:
22-24. (canceled)
26-27. (canceled)
A method of treating a subject having cancer or exhibiting a flare up of an autoimmune disease, comprising administering a binding composition derived from the antigen binding sites of antibodies, wherein the binding composition binds to IL-23R and CD161.
29-31. (canceled)
A composition for treatment of an autoimmune or proliferative disorder comprising two or more agents selected from the group consisting of an antagonist of IL-23, an antagonist of IL-1β, an antagonist of PGE2, an antagonist of IL-23 receptor, an antagonist of IL-1βreceptor, and an antagonist of a PGE2 receptor.
(canceled)
A method of generating pathogenic Th17 cells in vitro comprising culturing T cells in vitro in the presence of two or more agents selected from the group consisting of IL-23, IL-1β, and PGE2.
(canceled)
Dependencies are inferred from the claim text.